Telix Pharmaceuticals Stock Leads This ASX Growth Screen With Strong Insider Backing

Simply Wall St.

Aug 12

Oil prices are climbing on geopolitical risks and supply questions, and that is putting inflation and interest rate expectations back in the spotlight. When money gets more expensive, markets often ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2658395947"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658395947\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658395947?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","is_english":true,"pubTime":"2026-08-12 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658395947","market":"sg","top_or_hot":-1,"title":"Telix Pharmaceuticals Stock Leads This ASX Growth Screen With Strong Insider Backing","media":"Simply Wall St.","content":"<div>\n<p>Oil prices are climbing on geopolitical risks and supply questions, and that is putting inflation and interest rate expectations back in the spotlight. When money gets more expensive, markets often ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-leads-this-asx-growth-screen-wit\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals Stock Leads This ASX Growth Screen With Strong Insider Backing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals Stock Leads This ASX Growth Screen With Strong Insider Backing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-12 05:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-leads-this-asx-growth-screen-wit><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oil prices are climbing on geopolitical risks and supply questions, and that is putting inflation and interest rate expectations back in the spotlight. When money gets more expensive, markets often ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-leads-this-asx-growth-screen-wit\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7104","symbol_name":"黄金","start_time":0,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-leads-this-asx-growth-screen-wit","article_id":"2658395947","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-leads-this-asx-growth-screen-wit","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658395947","pubTimestamp":1786483757,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Oil prices are climbing on geopolitical risks and supply questions, and that is putting inflation and interest rate expectations back in the spotlight. When money gets more expensive, markets often start to reward companies that already have solid growth plans and committed insiders. This article looks at three stocks from the Fast Growing Stocks With High Insider Ownership screener that fit that bill and explains why they stand out now.\nThe three stocks highlighted next are just a starting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7104":"黄金","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","TLX.AU":"TELIX PHARMACEUTICALS LTD","PDI.AU":"PREDICTIVE DISCOVERY LTD","LIN.AU":"LINDIAN RESOURCES LTD","BK4139":"生物科技","BK7067":"生物科技","BK7095":"多种金属与采矿"},"translate_title":"Telix Pharmaceuticals 股票在强有力的内部支持下引领澳大利亚证券交易所增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIN.AU":1,"TLX.AU":1,"PDI.AU":1,"TLX":1.5},"content_text":"Oil prices are climbing on geopolitical risks and supply questions, and that is putting inflation and interest rate expectations back in the spotlight. When money gets more expensive, markets often start to reward companies that already have solid growth plans and committed insiders. This article looks at three stocks from the Fast Growing Stocks With High Insider Ownership screener that fit that bill and explains why they stand out now. The three stocks highlighted next are just a starting sample, and the full screen surfaced 99 more companies with equally compelling growth and insider ownership stories that are not covered here. To identify and analyze the setups that best fit your own conviction level, head straight to the Fast Growing Stocks With High Insider Ownership screener. AdvertisementPredictive Discovery (ASX:PDI) Predictive Discovery is a West Africa focused gold company with two producing mines and its flagship Bankan Gold project in north east Guinea, covering 356 square kilometres. The company is still in an early commercial phase and is targeting large scale future production from this portfolio. Predictive Discovery currently carries a market cap of about A$3.8b, which puts it firmly in mid to large cap territory on the ASX. Predictive Discovery provides exposure to a West African gold producer that is ramping up output at Kiniero and Nampala while advancing the Bankan project toward production. Analysts have published expectations of earnings and revenue growth over the next few years, supported by a reported 9.5 million ounce resource and 4.5 million ounces in reserves, while some estimates suggest the stock is trading below certain fair value assessments. The company is still loss making, has less than a year of cash runway and relies on external funding in higher risk jurisdictions, so permits, costs and financing are all important variables. Investors monitoring PDI may wish to keep these factors in mind when following future company developments. Predictive Discovery is ramping up a large resource base, yet still carries early stage risks around cash, permits and jurisdiction. Get the fuller picture in the 2 key rewards and 3 important warning signs (2 are major!) ASX:PDI Earnings & Revenue Growth as at Aug 2026 Build your own high growth and insider backed shortlist Predictive Discovery and the other two stocks here are just three examples that surfaced from a single screener. Use our flexible Screener to mix filters like growth, insider ownership, valuation and balance sheet strength, or tap into our curated Investing Ideas for ready made shortlists. Telix Pharmaceuticals (ASX:TLX) Telix Pharmaceuticals develops and sells radiopharmaceuticals that help doctors image and treat cancers, with products and pipeline programs across prostate, kidney, brain and other solid tumours. Most revenue currently comes from Precision Medicine at about $621.9 million, with Manufacturing Solutions contributing roughly $245.1 million and Therapeutics still a much smaller $9.3 million segment. The company is valued at around A$5.8b, which puts it in the larger end of the ASX healthcare space. Telix Pharmaceuticals sits at the crossroads of commercial radiopharmaceutical sales and a large late stage oncology pipeline. This is one reason it continues to draw interest despite recent share price weakness. The core imaging products Illuccix and Gozellix already generate hundreds of millions in sales, while multiple Phase 3 trials such as TLX591 and TLX250, plus the new Regeneron alliance, give the story additional potential if they progress as planned. At the same time, Telix is still unprofitable, spending heavily on R&D and manufacturing buildout, and relies on external funding, so execution, trial results and regulatory decisions carry real weight for future returns. Telix Pharmaceuticals sits at the point where commercial cancer imaging sales and late stage trials are starting to intersect, yet the full growth story still feels underappreciated. See how current expectations stack up in the analyst forecasts for Telix Pharmaceuticals ASX:TLX Earnings & Revenue Growth as at Aug 2026 Lindian Resources (ASX:LIN) Lindian Resources is a Perth based explorer focused on gold, bauxite and rare earths across Tanzania, Guinea, Malawi, Australia and Singapore, with its flagship Kangankunde Rare Earths project in Malawi. The company is still pre revenue, so the story is about future production potential rather than current sales. Lindian currently carries a market cap of about A$1.6b, which puts it in the mid cap bracket on the ASX. Lindian Resources sits at the centre of investor interest in rare earths, with the Kangankunde project in Malawi and a plan to link mine output to downstream processing at the SARECO facility in Kazakhstan from Q4 2026. The stock is still unprofitable, revenue is minimal and past losses have been rising, while shareholders have also experienced dilution and the balance sheet leans on higher risk external funding. That mix of very early stage financials, high forecast earnings and revenue growth, fresh board and management, and recent confirmation of Malawi licence validity makes Lindian a high risk, high potential rare earths story that many investors will want to understand better before taking a view. Lindian Resources is pitching a rare earths growth story that sits on early stage financials, rising past losses and fresh leadership changes. Get the context behind that risk reward stretch in the 1 key reward and 3 important warning signs (2 are major!) ASX:LIN Earnings & Revenue Growth as at Aug 2026 Seeking Fresh Alternatives Before They Fly Markets move fast and the next breakout list is often quietly building momentum under the radar. Scan these fresh ideas while the opportunity is still available.  Spot income workhorses that aim to keep payouts flowing even when prices wobble by checking the 4 dividend fortresses while the yields still look compelling. Follow the build-out of next generation compute and networking by scanning the 56 AI infrastructure stocks before capital potentially moves in and reprices the standouts. Track potential beneficiaries of electrification and urban upgrades using the 37 power grid technology and infrastructure stocks while these grid focused stocks remain under closer scrutiny.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Telix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}